When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
CAPR - Capricor's Latest DMD Data Makes It A Force To Be Reckoned With
Capricor Therapeutics Inc.
Capricor Therapeutics (CAPR) announced positive interim results from its phase 2 HOPE-2 study using CAP-1002 to treat patients with Duchenne muscular dystrophy ((DMD)). This is good news for this patient population as it needs more treatment options. The next step is for the biotech to meet with the FDA to discuss future plans of the program. It is likely that this trial will still have to be completed for the time being. It's possible that upon trial completion additional dialogue with the FDA could lead to a late-stage registration study for CAP-1002 in